Tau protein, beta-amyloid₁₋₄₂ and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia
Language English Country Netherlands Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
24928081
DOI
10.1016/j.jns.2014.05.052
PII: S0022-510X(14)00356-6
Knihovny.cz E-resources
- Keywords
- Alzheimer disease, Biomarkers, Cerebrospinal fluid, Clusterin, Lewy body dementia, Parkinson's disease,
- MeSH
- Amyloid beta-Peptides cerebrospinal fluid MeSH
- Dementia cerebrospinal fluid complications diagnosis MeSH
- Diagnosis, Differential MeSH
- Adult MeSH
- Enzyme-Linked Immunosorbent Assay MeSH
- Middle Aged MeSH
- Humans MeSH
- Parkinson Disease cerebrospinal fluid complications diagnosis MeSH
- Peptide Fragments cerebrospinal fluid MeSH
- tau Proteins cerebrospinal fluid MeSH
- Reproducibility of Results MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Sensitivity and Specificity MeSH
- Severity of Illness Index MeSH
- Mental Status Schedule MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- amyloid beta-protein (1-42) MeSH Browser
- Amyloid beta-Peptides MeSH
- Peptide Fragments MeSH
- tau Proteins MeSH
BACKGROUND: Parkinson's disease (PD), PD with dementia (PDD) and Lewy body dementia (DLB) are synucleinopathies. PDD and DLB are sometimes considered a transition between PD and Alzheimer dementia (AD). Finding in vivo markers or their combination could help in the differential diagnosis of these neurodegenerative (ND) diseases. OBJECTIVE: The aim of this study was to assess cerebrospinal fluid (CSF) levels of tau protein, betaamyloid1-42 and clusterin and to compare these levels among patients with probable PD, PDD, DLB and AD. METHODS: CSF levels of ND markers were assessed in 96 patients (27 patients with PD, 14 with PDD, 14 with DLB, 17 with AD and 24 subjects as a control group). RESULTS: In all of the groups of patients, beta-amyloid1-42 levels were decreasing in the order PD>PDD>DLB>AD, whereas tau protein and the tau protein/beta-amyloid1-42 index were increasing in the same order (PD
References provided by Crossref.org
